Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) Short Interest Down 44.9% in May

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT - Get Free Report) was the target of a large decrease in short interest in the month of May. As of May 31st, there was short interest totalling 24,200 shares, a decrease of 44.9% from the May 15th total of 43,900 shares. Based on an average daily trading volume, of 183,500 shares, the short-interest ratio is currently 0.1 days. Approximately 0.0% of the company's shares are short sold.

Institutional Trading of Xtant Medical

An institutional investor recently raised its position in Xtant Medical stock. Renaissance Technologies LLC increased its stake in Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT - Free Report) by 15.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 798,033 shares of the medical device company's stock after acquiring an additional 103,825 shares during the period. Renaissance Technologies LLC owned approximately 0.57% of Xtant Medical worth $354,000 at the end of the most recent reporting period. 69.33% of the stock is currently owned by hedge funds and other institutional investors.

Xtant Medical Trading Down 4.2%

Shares of XTNT stock traded down $0.03 during trading hours on Friday, hitting $0.62. The company had a trading volume of 19,320 shares, compared to its average volume of 121,212. The company's fifty day moving average is $0.57 and its 200 day moving average is $0.52. The company has a debt-to-equity ratio of 0.42, a current ratio of 2.12 and a quick ratio of 0.88. Xtant Medical has a fifty-two week low of $0.33 and a fifty-two week high of $0.83. The stock has a market capitalization of $86.53 million, a PE ratio of -4.79 and a beta of 0.35.

Xtant Medical Company Profile

Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.